Bristol-Myers Squibb and Pfizer have announced that federal regulators have expanded approval of their blood thinner Eliquis to treat Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE).
The Food and Drug Administration cleared the drug for patients suffering from or at risk of the two types of dangerous blood clots. The drug was originally approved in 2012 to treat a common form of irregular heartbeat, atrial fibrillation, in patients at risk for strokes or dangerous clots.
Eliquis, known chemically as apixaban, is manufactured by Bristol-Myers Squibb and co-marketed with Pfizer. Both companies are based in New York.
"We are pleased that Eliquis is now available as an effective treatment option for Deep Vein Thrombosis and Pulmonary Embolism. It offers oral dosing, no routine coagulation testing, and does not require the use of a parenteral anticoagulant or bridging during initiation," said Douglas Manion, M.D., Head of Specialty Development, Bristol-Myers Squibb.